Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Japan’s first reported RiHEART transplant after the treatment became eligible for public health insurance took place on September 29, 2026, at Osaka Police Hospital. It marks a move from clinical-trial use to treatment under a conditionally approved, insured product—not the first-ever transplant of an iPS-cell-derived heart-cell sheet, and not evidence that the therapy is suitable for everyone with heart disease.
What happened in Japan
Cuorips announced on October 1, 2026, that a patient received RiHEART at Osaka Police Hospital on September 29. The product became eligible for Japan’s public health insurance system on September 1. Cuorips described the procedure as the first transplantation after insurance coverage began. Cuorips’ announcement establishes the timing and milestone; it should be understood as the first reported insured use, not the first human use.
Jiji Press, in a report carried by Nippon.com on September 30, described the recipient as a woman in her 50s with severe heart failure and reported that her condition was stable after surgery. That is an early post-operative description, not a measure of long-term recovery or proof of efficacy. Nippon.com’s report provides that patient detail.
What RiHEART is and who it is intended for
RiHEART is a sheet of cardiomyocytes—heart muscle cells—derived from allogeneic induced pluripotent stem cells (iPS cells). Allogeneic means the cells come from a donor rather than being made from the recipient’s own cells. Cuorips says the sheet is applied to the heart’s surface. The company describes a proposed mechanism in which cytokines and other substances released by the cells may act on the heart; that is an intended mechanism, not established proof of clinical benefit. Cuorips’ product information describes the product and its intended use.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
Intended indication
The company describes RiHEART as intended for severe heart failure caused by ischemic cardiomyopathy that remains refractory to standard pharmacological and invasive therapies. Ischemic cardiomyopathy is heart muscle damage associated with inadequate blood supply, commonly related to coronary artery disease. This narrow indication does not make RiHEART a general treatment for heart failure, other heart conditions, or anyone seeking regenerative medicine.
Approval and insurance coverage are different milestones
Japan’s Ministry of Health, Labour and Welfare granted RiHEART conditional, time-limited marketing approval on March 6, 2026, according to the Japan Agency for Medical Research and Development (AMED). AMED identifies Cuorips as the developer and says the product is based on research by Professor Yoshiki Sawa’s group at the University of Osaka. AMED’s approval announcement describes the date and research lineage.
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
Under Japan’s conditional approval pathway, a product may be approved when safety has been confirmed and efficacy is reasonably predicted, subject to conditions and a time limit. The approval framework calls for efficacy to be confirmed and safety evaluated after marketing, followed by an application for full approval within the designated period. Conditional marketing approval is therefore not the same as completed confirmation of long-term effectiveness.
Insurance eligibility began September 1, 2026, according to Cuorips. That date concerns coverage in Japan; it does not establish that every patient can receive RiHEART, that treatment is available at every hospital, or that a procedure is appropriate for a particular person. The sources cited here do not specify an individual patient’s coverage determination or the practical access process.
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
The post-coverage procedure is not the first RiHEART-era transplant
Transplantation of iPS-derived heart-cell sheets began in clinical research before the 2026 insurance milestone. AMED and the University of Osaka reported that the first participant in an investigator-initiated trial for ischemic cardiomyopathy received a transplant in January 2020; the study was planned for 10 cases. AMED’s January 27, 2020 report documents that earlier research milestone.
The distinction matters: the September 2026 procedure was the first reported transplant after RiHEART became insurance-eligible, whereas the 2020 procedure was part of an earlier clinical-trial program. Calling the 2026 operation the first-ever human transplant would erase that history.
Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
What the first operation does—and does not—show
A transplant taking place is evidence that the treatment has moved into use after approval and insurance coverage. A patient reported stable shortly after surgery is not evidence, by itself, that RiHEART improves survival, heart function, symptoms, or quality of life over the longer term. Nor does one operation establish the frequency of complications or durability of any benefit.
Evidence-gathering continues. Japan’s clinical-trial registry lists a separate interventional study of allogeneic iPS-derived cardiomyocyte sheets for dilated cardiomyopathy, with a target enrollment of four. Its outcomes include adverse events, serious adverse events and cardiac clinical events through 52 weeks, alongside measures such as left-ventricular function, heart-failure severity, exercise tolerance, rejection events and whether participants are judged improved. These are planned measures, not reported results. The registry entry describes that study; its target size and endpoints should not be mistaken for findings about RiHEART’s effectiveness.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Scan for outdated or missing drivers - takes under a minute3Repair Windows errors before they cause bigger problemsBest Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
What patients and families should ask
RiHEART’s narrow indication and conditional status make decisions dependent on an individual’s diagnosis, treatment history and specialist assessment. Patients should discuss these points with their heart-failure team rather than infer eligibility from the news about the first post-coverage operation:
- Is the heart failure specifically caused by ischemic cardiomyopathy, and is it severe and refractory to the standard treatments relevant to the patient?
- Does the patient meet the product’s approved conditions, and is a hospital able to provide the treatment?
- What benefits are established for the patient’s situation, what remains uncertain, and what risks or follow-up requirements apply?
- How does this option fit alongside other appropriate treatments, based on the patient’s condition and the evidence available?
The sources cited here do not establish comparative effectiveness against other heart-failure treatments or supply a complete patient-level eligibility and access protocol; those questions require current advice from the treating specialists and the relevant hospital.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
